Low ERCC1 Expression in Malignant Pleural Mesotheliomas Treated with Cisplatin and Vinorelbine Predicts Prolonged Progression-Free Survival
| Autor: | Cecilia Bech, Zarah Glad Zimling, Claus B. Andersen, Eric Santoni-Rugiu, Jens Benn Sørensen, Thomas A. Gerds |
|---|---|
| Rok vydání: | 2012 |
| Předmět: |
Adult
Male Mesothelioma Pulmonary and Respiratory Medicine medicine.medical_specialty Pathology Pleural Neoplasms Kaplan-Meier Estimate Vinblastine Vinorelbine Gastroenterology Disease-Free Survival Predictive Value of Tests Internal medicine Antineoplastic Combined Chemotherapy Protocols Biomarkers Tumor Confidence Intervals medicine Humans Progression-free survival Aged Proportional Hazards Models Retrospective Studies Proportional hazards model business.industry Hazard ratio Retrospective cohort study Middle Aged Endonucleases Immunohistochemistry DNA-Binding Proteins Treatment Outcome Oncology Predictive value of tests Population study Female Cisplatin ERCC1 business medicine.drug |
| Zdroj: | Journal of Thoracic Oncology. 7:249-256 |
| ISSN: | 1556-0864 |
| DOI: | 10.1097/jto.0b013e318233d6a9 |
| Popis: | Introduction The relationship between excision repair cross-complementation group 1 (ERCC1) expression and outcome, in patients with malignant pleural mesothelioma (MPM), treated with cisplatin/vinorelbine combination-therapy, was retrospectively evaluated in a patient population from a previously published phase II clinical trial. Methods The study population consisted of 54 inoperable patients with MPM enrolled between 2003 and 2006. ERCC1 expression was evaluated by immunohistochemistry (IHC) on the formalin-fixed paraffin-embedded diagnostic biopsies. The immunoreaction was quantified using an H-score (staining intensity multiplied by a proportion score based on the percentage of stained tumor cells). The cutoff point was chosen as the median H-score in a cohort of non-neoplastic pleural samples from patients with benign thoracic diseases. The tumor samples were separated according to this cutoff point into ERCC1-negative (H-score ≤ median) and ERCC1-positive (H-score > median) cases. Results Fifty patients had tumor tissue available for IHC. There were 20 ERCC1-positive and 30 ERCC1-negative tumors. There was a significant correlation between negative ERCC1 status and long progression-free survival (PFS). Median PFS was 10.9 months in the ERCC1-negative group, opposed to 6.7 months in the ERCC1-positive group ( p = 0.053). Multivariate Cox regression showed ERCC1 to be the only variable significantly associated with PFS, and ERCC1-positive patients had a significantly shorter time to progression compared with ERCC1-negative patients (hazard ratios, 2.24; 95% confidence interval, 1.16–4.34; p = 0.0163). We found no association between ERCC1 status and overall survival. Conclusion Our retrospective study in MPM patients treated with cisplatin/vinorelbine suggests that low ERCC1 expression, evaluated by IHC, may predict longer PFS, a result that warrants further validation. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|